Gummadi Surya

CTSH President Americas sells 7,000 shares at $81.42; stock now at $84.62 (+4.8% in 30 days)

Gummadi Surya, President of Americas at Cognizant, sold 7,000 shares (20.4% of pre-transaction holdings) on 2026-01-02 at $81.42 per share for $569,962.40. The stock has since appreciated to $84.62 (+4.8% over the past 30 days and +23.7% over 90 days), suggesting the sale timing was not advantageous from a price-appreciation perspective. His prior two CTSH sales (2025-12-01 and 2025-11-26) also showed positive 30-day returns of +6.6% and +11.0% respectively, indicating a pattern of selling before rallies. At a market cap of $40.8B with stable fundamentals (P/E 19.19, annual revenue growth +2.0%), the company appears soundly valued, and this sale does not signal acute fundamental concerns.

Gummadi Surya (President – Americas, CTSH) sold 7,000 shares at $77.84 on 2025-12-01; holds 33,229 shares post-sale.

Gummadi Surya, President – Americas at Cognizant, sold 7,000 shares for $544,890.50 at $77.84, reducing his position by 17.4% to 33,229 shares. The sale occurred when the stock was trading 12.6% below its 52-week high of $90.70, and the current price of $79.24 is marginally above the transaction price. His cross-ticker track record shows only 1 prior sell, and at CTSH specifically, this follows another sale just five days prior on 2025-11-26, indicating consecutive open-market dispositions. Without measurable 90-day outcome data on the prior CTSH sale or evidence of a scheduled trading plan, the pattern of two sequential sells in late November and early December warrants monitoring for context (whether discretionary or part of a pre-arranged schedule).

Gummadi Surya (President - Americas) sold 7,000 shares of CTSH at $77.08, reducing holdings by 15.1%

Gummadi Surya, serving as President - Americas, sold 7,000 shares at $77.08 on 2025-11-26 for a total of $539,578.20, leaving post-transaction holdings of 39,319 shares. The sale represents a 15.1% reduction in his shareholdings. The stock is currently trading at $77.43, just 30 basis points above the sale price, and remains 14.6% below its 52-week high of $90.70, despite positive momentum over the past 30 days (+6.2%) and 90 days (+7.9%). With a single prior sell in his cross-ticker track record and no measurable outcome yet from a prior sale at this ticker on 2025-12-01, this transaction provides limited evidence of an established selling pattern at CTSH. The company's fundamentals show net income of $274,000,000 on revenue of $5,415,000,000 with modest annual revenue growth of 2.0% and a P/E of 17.56.